These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 4217252)

  • 1. Assessment of antipsychotic activity of a butyrophenone analogue, lenperone (AHR 2277).
    Sathanathan GL; Angrist BM; Phillips N; Gershon S
    Curr Ther Res Clin Exp; 1974 Aug; 16(8):844-7. PubMed ID: 4217252
    [No Abstract]   [Full Text] [Related]  

  • 2. An early clinical trial of lenperone (AHR 2277), a butyrophenone, in chronic schizophrenia.
    Simpson GM; Varga V
    Curr Ther Res Clin Exp; 1974 May; 16(5):477-82. PubMed ID: 4209063
    [No Abstract]   [Full Text] [Related]  

  • 3. Further studies of the butyrophenone, CI-601, in chronic schizophrenic patients.
    Edwards JG; Simpson GM
    Curr Ther Res Clin Exp; 1968 Oct; 10(10):520-8. PubMed ID: 4971467
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of acute schizophrenia with a new butyrophenone-lenperone.
    Harris M
    J Clin Pharmacol; 1975; 15(2-3):187-90. PubMed ID: 1091666
    [No Abstract]   [Full Text] [Related]  

  • 5. Pilot open-label study of lenperone (AHR 2277), a butyrophenone, in anxiety.
    Fabre LF; Harris RT
    Curr Ther Res Clin Exp; 1976 Mar; 19(3):328-31. PubMed ID: 817861
    [No Abstract]   [Full Text] [Related]  

  • 6. Lenperone: a controlled evaluation in chronic schizophrenic patients.
    Mielke DH; Gallant DM; Kessler C; Roniger JJ
    Curr Ther Res Clin Exp; 1975 Nov; 18(5):636-40. PubMed ID: 812640
    [No Abstract]   [Full Text] [Related]  

  • 7. A pilot study of CI-601 in chronic schizophrenics.
    Sugerman AA; Herrmann J; O'Hara M
    Curr Ther Res Clin Exp; 1968 Oct; 10(10):529-32. PubMed ID: 4971468
    [No Abstract]   [Full Text] [Related]  

  • 8. Antipsychotic effects, side effects and effective dosis of the butyrophenone lenperone (AHR 2277).
    Woggon B; Franke A; Hucker H; Ruether E; Athen D; Angst J; Hippius H
    Int Pharmacopsychiatry; 1977; 12(2):113-26. PubMed ID: 561037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind comparison of AL-1021 and chlorpromazine in hospitalized schizophrenics.
    Gendron JL; Zimmermann RL; Schiele BC
    Curr Ther Res Clin Exp; 1973 Jun; 15(6):333-6. PubMed ID: 4197258
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential value of penfluridol and pipothiazine palmitate.
    Gallant DM
    Psychopharmacol Bull; 1975 Jan; 11(1):11-2. PubMed ID: 235769
    [No Abstract]   [Full Text] [Related]  

  • 11. A double-blind study of melperone and placebo in hospitalized chronic alcoholics in postintoxication phase.
    Carlsson C; Gullberg B; Höstery U; Christensson E
    Int J Clin Pharmacol Biopharm; 1979 Aug; 17(8):341-5. PubMed ID: 39900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CI-601, a butyrophenone derivative, in the treatment of chronically withdrawn schizophrenic patients.
    Villeneuve C; Ananth JV; Ban TA; Lehmann HE
    Curr Ther Res Clin Exp; 1970 Apr; 12(4):223-9. PubMed ID: 4985943
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical evaluation of a butyrophenone derivative, methylperidol, in 40 cases of schizophrenia and other psychoses].
    Vinci M
    Osp Psichiatr; 1971; 39(2):399-407. PubMed ID: 4948707
    [No Abstract]   [Full Text] [Related]  

  • 14. A pilot study on the use of AL-1021 in the treatment of acute schizophrenics.
    Gendron JL; Schiele BC
    Curr Ther Res Clin Exp; 1971 Mar; 13(3):169-73. PubMed ID: 4998288
    [No Abstract]   [Full Text] [Related]  

  • 15. Haloperidol--new addition to the drug treatment of schizophrenia.
    Stewart A; Lafave HG; Segovia G
    Behav Neuropsychiatry; 1969 Oct; 1(7):23-8. PubMed ID: 4907607
    [No Abstract]   [Full Text] [Related]  

  • 16. [Controlled comparative study of methylperidol and perphenazine in schizoprenic psychoses].
    Svestka J; Náhunek K
    Act Nerv Super (Praha); 1970 Jan; 12(1):57-8. PubMed ID: 4907391
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of the clinical effects of timiperone, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique.
    Kariya T; Shimazono Y; Itoh H; Mori A; Murasaki M; Sugano K; Toru M; Yamashita I
    J Int Med Res; 1983; 11(2):66-77. PubMed ID: 6133803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Report on an open investigation on bromperidol, a neuroleptic of the butyrophenone series].
    Fleischhauer J
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():30-7. PubMed ID: 35476
    [No Abstract]   [Full Text] [Related]  

  • 19. Pilot study on the use of AL-1021 in the treatment of chronic schizophrenia.
    Angus JW; Go SH; Simpson GM
    Curr Ther Res Clin Exp; 1969 Dec; 11(12):779-83. PubMed ID: 4984043
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison of triperidol with perphenazine in schizophrenic psychoses. Effect on the photomyoclonic threshold].
    Náhunek K; Hádlík J; Rodová A; Misurec J; Vanýsek J
    Act Nerv Super (Praha); 1970 Jan; 12(1):56-7. PubMed ID: 4907390
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.